Wait, we have a special offer for you! ✋

Get your exclusive discount now

YES, get the discount! No, I'd pay the full price
Global Axial Spondyloarthritis axSpA Market Report 2024

Axial Spondyloarthritis (axSpA) Global Market Report 2024 – By Types (Ankylosing spondylitis (AS), Non-radiographic axial spondyloarthritis (nr-axSpA)), By Commercialized Therapies (Anti-tumor Necrosis Factor Therapy (TNF), Anti-Interleukin Therapy (IL), Anti-Janus Kinase Therapy (JAK)), By Dosage Form (Tablets, Injections), By Treatment (Tumor necrosis factor (TNF) Alpha Inhibitors, Non-steroidal anti-inflammatory drugs (NSAID), Conventional Disease Modifying Anti-Rheumatic Drugs, Glucocorticoids, Interleukin Blockers), By End-Use (Hospital Pharmacies, Retailer Pharmacies, Online Pharmacy Stores) – Market Size, Trends, And Global Forecast 2024-2033

Axial Spondyloarthritis (axSpA) Global Market Report 2024

Starting Price : $5000.00 | Pages : | Published : January 2024 | Delivery Time: 2-3 business days | Format : pdf

Purchase Options
Request Sample
Request For Discount
Customise Your Report
Request For Proposal
Request For Regional Data
FAQs

Need assistance or more information before the purchase?

Enquire Before Buying
Axial Spondyloarthritis (axSpA) Global Market Report 2024

Proud Members Of

checkslacipN checkaoirsN checkscipN
Description Table Of Contents Tables & Figures Market Insights Related Reports

Axial Spondyloarthritis (Axspa) Market Definition And Segments

Axial Spondyloarthritis (axSpA) is a chronic inflammatory condition that predominantly impacts the axial skeleton, encompassing the spine and sacroiliac joints. It is characterized by inflammation in the sacroiliac joints, resulting in persistent back pain and stiffness.

The main types of axial spondyloarthritis (axSpA) are ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA). Ankylosing spondylitis (AS) refers to a form of arthritis that damages the ligaments and joints in the spine, where over-the-counter anti-inflammatory medications, such as naproxen and ibuprofen, are commonly used to relieve pain, inflammation, and muscle stiffness to delay complications and spinal deformities. The various commercialized therapies include anti-tumor necrosis factor therapy (TNF), anti-interleukin therapy (IL), and anti-janus kinase therapy (JAK) in different dosage forms such as tablets and injections for different types of treatments such as tumor necrosis factor (TNF) alpha inhibitors, non-steroidal anti-inflammatory drugs (NSAID), conventional disease modifying anti-rheumatic drugs, glucocorticoids, and interleukin blockers. These are sold by different end-users such as hospital pharmacies, retailer pharmacies, and online pharmacy stores.

The axial spondyloarthritis (axSpA) market covered in this report is segmented –

1) By Types: Ankylosing spondylitis (AS), Non-radiographic axial spondyloarthritis (nr-axSpA)

2) By Commercialized Therapies: Anti-tumor Necrosis Factor Therapy (TNF), Anti-Interleukin Therapy (IL), Anti-Janus Kinase Therapy (JAK)

3) By Dosage Form: Tablets, Injections

4) By Treatment: Tumor necrosis factor (TNF) Alpha Inhibitors, Non-steroidal anti-inflammatory drugs (NSAID), Conventional Disease Modifying Anti-Rheumatic Drugs, Glucocorticoids, Interleukin Blockers

5) By End-Use: Hospital Pharmacies, Retailer Pharmacies, Online Pharmacy Stores

The axial spondyloarthritis (axSpA) market size has grown strongly in recent years. It will grow from $5.54 billion in 2023 to $6.04 billion in 2024 at a compound annual growth rate (CAGR) of 9.0%. The growth in the historic period can be attributed to improved diagnostic criteria, biological treatment advancements, rising disease awareness, genetic research advances, clinical trial progress.

The axial spondyloarthritis (axSpA) market size is expected to see strong growth in the next few years. It will grow to $8.18 billion in 2028 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period can be attributed to advancements in biomarker identification, tailored therapies, digital health integration, expanded treatment options, healthcare policy support. Major trends in the forecast period include early intervention strategies, patient-centric care, telemedicine and remote consultations, research on disease mechanisms, shared decision-making.

Rising Prevalence Of Axial Spondyloarthritis (AXSPA) Is A Catalyst For Market Growth And Advancements In Treatment

The increasing prevalence of spondyloarthritis is expected to propel the growth of the axial spondyloarthritis (axSpa) market going forward. Spondyloarthritis is a chronic illness that typically affects the axial skeleton, including the spine and sacroiliac joints. The rising cases of spondyloarthritis (axSpA) can be associated with the increasing aging population and spine injuries from even minor falls or other accidents, where various treatments are provided for pain management, inflammation control, and enhancing the patient's quality of life suffering from axSpA. For instance, in June 2023, according to Versus Arthritis's Musculoskeletal Health Report 2023, a UK-based charity dedicated to supporting people with arthritis, as of the year 2022, around 60,000 individuals were afflicted with axial spondyloarthritis, and annually, approximately 2,200 adults receive a new diagnosis for this condition. Therefore, the increasing prevalence of axial spondyloarthritis (axSpa) is driving the growth of the axial spondyloarthritis (axSpa) market.

Demographic Shifts And The Rising Aging Population Is A Catalyst For Axial Spondyloarthritis (AXSPA) Market Growth

The increasing aging population is expected to propel the growth of the axial spondyloarthritis (axSpa) market going forward. Aging population refers to a demographic trend characterized by an increasing proportion or a higher percentage of elderly individuals within a population. The benefits of addressing and managing axSpA in the aging population include improved joint function and mobility, improved quality of life, prevention of structural damage to the spine, reduced healthcare costs, prevention of disability, and optimized treatment strategies. For instance, in October 2022, according to the World Health Organization, a US-based specialized health agency, Globally, 1 in 6 people will be 60 or older by 2030, and there will be double the number of individuals in this age group (2.1 billion) by 2050. Additionally, for instance, in June 2021, according to the UK Parliament's House of Commons Library, a UK-based information resource, by 2043, there will be a rise in the senior population in the UK, which will make up 24% of the total population (17.4 million people). Therefore, the increasing aging population is driving the growth of the axial spondyloarthritis (axSpa) market.

Major companies operating in the axial spondyloarthritis (axspa) market report are Johnson and Johnson Private Limited, Pfizer Inc., F. Hoffmann-La Roche AG, Merck and Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A, Bristol-Myers Squibb Company, AstraZeneca plc., Abbott Laboratories, GSK plc., Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Biogen Inc., Vertex Pharmaceuticals Incorporated, UCB S.A., Boehringer Ingelheim International GmbH., Horizon Therapeutics Public Ltd Co, Mitsubishi Tanabe Pharma Corporation, Ipsen Technologies Pvt Ltd., Kyowa Kirin Co. Ltd., Sun Pharmaceutical Industries Ltd., Acelyrin Inc., Nordic Bioscience A/S, Iroko Pharmaceuticals LLC, Celgene Corporation, Pozen Inc.

UCB Sa Secures Eu Approval For Bimzelx In Treating Axial Spondyloarthritis (AXSPA)

Product innovations are the key trend gaining popularity in the axial spondyloarthritis (axSpA) market. Major companies operating in the axial spondyloarthritis (axSpA) market are developing new drugs to sustain their position in the market. For instance, in June 2023, UCB SA, a Belgium-based pharmaceutical company, received approval from the New European Commission for the marketing authorization of BIMZELX (bimekizumab). This medication is used to treat adults with active axial spondyloarthritis (axSpA), non-radiographic axial spondyloarthritis (nr-axSpA), and ankylosing spondylitis (AS) with objective signs of inflammation as indicated by elevated C-reactive protein. These European Union (EU) authorizations represent the drug's first global marketing licenses for axial spondyloarthritis.

Strategic Investment Paving Axial Spondyloarthritis Market

Major companies operating in the axial spondyloarthritis (axSpA) market are focusing on investments to gain a competitive edge in the market. This investment is for the development of Izokibep, a unique IL-17A inhibitor, to treat inflammatory diseases, including psoriatic arthritis (PsA) and axial spondyloarthritis (AxSpA). For instance, in September 2022, Acelyrin Inc., a US-based biopharma company announced an investment of $300 million. Izokibep is a mimetic antibody that mimics interleukin-17A (IL-17A) to circumvent the drawbacks of monoclonal antibodies. It has demonstrated good toleration in clinical trials. The investment aims to promote Izokibep's potential approval as a treatment for various inflammatory disorders and to further the drug's clinical development. The company's dedication to providing groundbreaking immunology therapies and meeting unmet medical needs for the treatment of inflammatory illnesses is evident in its focus on obtaining significant funding and progressing the development of Izokibep.

UCB SA And Ampersand Health Forge Strategic Partnership To Revolutionize Axial Spondyloarthritis (Axspa) Care Through Innovative Digital Solutions

In April 2022, Ampersand Health, a UK-based research company, partnered with UCB SA for an undisclosed amount. Through this partnership, both companies aim to help patients suffering from axial spondyloarthritis (axSpA) by combining their innovative digital solutions and clinical expertise to manage their symptoms and improve their quality of life. UCB SA is a Belgium-based biopharmaceutical company focusing on neurology and immunology therapies and providing solutions for axial spondyloarthritis.

North America was the largest region in the axial spondyloarthritis(axSpA) market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the axial spondyloarthritis (axSpA) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the axial spondyloarthritis (axSpA) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The axial spondyloarthritis (axSpA) market consists of revenues earned by entities by providing physical examinations, blood tests, magnetic resonance imaging (MRI) scans, and X-ray scans. The market value includes the value of related goods sold by the service provider or included within the service offering. The axial spondyloarthritis (axSpA) market also includes sales of analgesics, biologics, ibuprofen, naproxen, and diclofenac. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The axial spondyloarthritis (axSpA) market research report is one of a series of new reports from The Business Research Company that provides axial spondyloarthritis (axSpA) market statistics, including axial spondyloarthritis (axSpA) industry global market size, regional shares, competitors with an axial spondyloarthritis (axSpA) market share, detailed axial spondyloarthritis (axSpA) market segments, market trends and opportunities, and any further data you may need to thrive in the axial spondyloarthritis (axSpA) industry. This axial spondyloarthritis (axSpA) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Axial Spondyloarthritis (axSpA) Market Report Scope
Report AttributeDetails
Market Size Value In 2024 $6.04 billion
Revenue Forecast In 2033 $8.18 billion
Growth Rate CAGR of 7.9% from 2024 to 2033
Base Year For Estimation 2023
Actual Estimates/Historical Data 2018-2023
Forecast Period 2024 - 2028 - 2033
Market Representation Revenue in USD Billion and CAGR from 2024 to 2033
Segments Covered 1) By Types: Ankylosing spondylitis (AS), Non-radiographic axial spondyloarthritis (nr-axSpA)
2) By Commercialized Therapies: Anti-tumor Necrosis Factor Therapy (TNF), Anti-Interleukin Therapy (IL), Anti-Janus Kinase Therapy (JAK)
3) By Dosage Form: Tablets, Injections
4) By Treatment: Tumor necrosis factor (TNF) Alpha Inhibitors, Non-steroidal anti-inflammatory drugs (NSAID), Conventional Disease Modifying Anti-Rheumatic Drugs, Glucocorticoids, Interleukin Blockers
5) By End-Use: Hospital Pharmacies, Retailer Pharmacies, Online Pharmacy Stores
Regional Scope Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Country Scope Australia; China; India; Indonesia; Japan; South Korea; Bangladesh; Thailand; Vietnam; Malaysia; Singapore; Philippines; Hong Kong; New Zealand; USA; Canada; Mexico; Brazil; Chile; Argentina; Colombia; Peru; France; Germany; UK; Austria; Belgium; Denmark; Finland; Ireland; Italy; Netherlands; Norway; Portugal; Spain; Sweden; Switzerland; Russia; Czech Republic; Poland; Romania; Ukraine; Saudi Arabia; Israel; Iran; Turkey; UAE; Egypt; Nigeria; South Africa
Key Companies Profiled Johnson and Johnson Private Limited; Pfizer Inc.; F. Hoffmann-La Roche AG; Merck and Co. Inc.; AbbVie Inc.; Novartis AG; Sanofi S.A; Bristol-Myers Squibb Company; AstraZeneca plc.; Abbott Laboratories; GSK plc.; Eli Lilly and Company; Takeda Pharmaceutical Company Limited; Gilead Sciences Inc.; Teva Pharmaceutical Industries Ltd.; Regeneron Pharmaceuticals Inc.; Biogen Inc.; Vertex Pharmaceuticals Incorporated; UCB S.A.; Boehringer Ingelheim International GmbH.; Horizon Therapeutics Public Ltd Co; Mitsubishi Tanabe Pharma Corporation; Ipsen Technologies Pvt Ltd.; Kyowa Kirin Co. Ltd.; Sun Pharmaceutical Industries Ltd.; Acelyrin Inc.; Nordic Bioscience A/S; Iroko Pharmaceuticals LLC; Celgene Corporation; Pozen Inc.
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

    Table Of Contents

    1. Executive Summary

    2. Axial Spondyloarthritis (axSpA) Market Characteristics

    3. Axial Spondyloarthritis (axSpA) Market Trends And Strategies

    4. Axial Spondyloarthritis (axSpA) Market - Macro Economic Scenario

    4.1. Impact Of High Inflation On The Market

    4.2. Ukraine-Russia War Impact On The Market

    4.3. COVID-19 Impact On The Market

    5. Global Axial Spondyloarthritis (axSpA) Market Size and Growth

    5.1. Global Axial Spondyloarthritis (axSpA) Market Drivers and Restraints

    5.1.1. Drivers Of The Market

    5.1.2. Restraints Of The Market

    5.2. Global Axial Spondyloarthritis (axSpA) Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)

    5.3. Global Axial Spondyloarthritis (axSpA) Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

    6. Axial Spondyloarthritis (axSpA) Market Segmentation

    6.1. Global Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Ankylosing spondylitis (AS)

    Non-radiographic axial spondyloarthritis (nr-axSpA)

    6.2. Global Axial Spondyloarthritis (axSpA) Market, Segmentation By Commercialized Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Anti-tumor Necrosis Factor Therapy (TNF)

    Anti-Interleukin Therapy (IL)

    Anti-Janus Kinase Therapy (JAK)

    6.3. Global Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Tablets

    Injections

    6.4. Global Axial Spondyloarthritis (axSpA) Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Tumor necrosis factor (TNF) Alpha Inhibitors

    Non-steroidal anti-inflammatory drugs (NSAID)

    Conventional Disease Modifying Anti-Rheumatic Drugs

    Glucocorticoids

    Interleukin Blockers

    6.5. Global Axial Spondyloarthritis (axSpA) Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Hospital Pharmacies

    Retailer Pharmacies

    Online Pharmacy Stores

    7. Axial Spondyloarthritis (axSpA) Market Regional And Country Analysis

    7.1. Global Axial Spondyloarthritis (axSpA) Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    7.2. Global Axial Spondyloarthritis (axSpA) Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8. Asia-Pacific Axial Spondyloarthritis (axSpA) Market

    8.1. Asia-Pacific Axial Spondyloarthritis (axSpA) Market Overview

    Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8.3. Asia-Pacific Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8.4. Asia-Pacific Axial Spondyloarthritis (axSpA) Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    9. China Axial Spondyloarthritis (axSpA) Market

    9.1. China Axial Spondyloarthritis (axSpA) Market Overview

    9.2. China Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    9.3. China Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    9.4. China Axial Spondyloarthritis (axSpA) Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    10. India Axial Spondyloarthritis (axSpA) Market

    10.1. India Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    10.2. India Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    10.3. India Axial Spondyloarthritis (axSpA) Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11. Japan Axial Spondyloarthritis (axSpA) Market

    11.1. Japan Axial Spondyloarthritis (axSpA) Market Overview

    11.2. Japan Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11.3. Japan Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11.4. Japan Axial Spondyloarthritis (axSpA) Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12. Australia Axial Spondyloarthritis (axSpA) Market

    12.1. Australia Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12.2. Australia Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12.3. Australia Axial Spondyloarthritis (axSpA) Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13. Indonesia Axial Spondyloarthritis (axSpA) Market

    13.1. Indonesia Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13.2. Indonesia Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13.3. Indonesia Axial Spondyloarthritis (axSpA) Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14. South Korea Axial Spondyloarthritis (axSpA) Market

    14.1. South Korea Axial Spondyloarthritis (axSpA) Market Overview

    14.2. South Korea Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14.3. South Korea Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14.4. South Korea Axial Spondyloarthritis (axSpA) Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15. Western Europe Axial Spondyloarthritis (axSpA) Market

    15.1. Western Europe Axial Spondyloarthritis (axSpA) Market Overview

    15.2. Western Europe Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15.3. Western Europe Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15.4. Western Europe Axial Spondyloarthritis (axSpA) Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16. UK Axial Spondyloarthritis (axSpA) Market

    16.1. UK Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16.2. UK Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16.3. UK Axial Spondyloarthritis (axSpA) Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17. Germany Axial Spondyloarthritis (axSpA) Market

    17.1. Germany Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17.2. Germany Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17.3. Germany Axial Spondyloarthritis (axSpA) Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18. France Axial Spondyloarthritis (axSpA) Market

    18.5. France Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18.6. France Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18.7. France Axial Spondyloarthritis (axSpA) Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19. Italy Axial Spondyloarthritis (axSpA) Market

    19.9. Italy Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19.10. Italy Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19.11. Italy Axial Spondyloarthritis (axSpA) Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20. Spain Axial Spondyloarthritis (axSpA) Market

    20.13. Spain Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20.14. Spain Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20.15. Spain Axial Spondyloarthritis (axSpA) Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21. Eastern Europe Axial Spondyloarthritis (axSpA) Market

    21.1. Eastern Europe Axial Spondyloarthritis (axSpA) Market Overview

    21.2. Eastern Europe Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21.3. Eastern Europe Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21.4. Eastern Europe Axial Spondyloarthritis (axSpA) Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22. Russia Axial Spondyloarthritis (axSpA) Market

    22.1. Russia Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22.2. Russia Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22.3. Russia Axial Spondyloarthritis (axSpA) Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23. North America Axial Spondyloarthritis (axSpA) Market

    23.1. North America Axial Spondyloarthritis (axSpA) Market Overview

    23.2. North America Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23.3. North America Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23.4. North America Axial Spondyloarthritis (axSpA) Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24. USA Axial Spondyloarthritis (axSpA) Market

    24.1. USA Axial Spondyloarthritis (axSpA) Market Overview

    24.2. USA Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24.3. USA Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24.4. USA Axial Spondyloarthritis (axSpA) Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25. Canada Axial Spondyloarthritis (axSpA) Market

    25.1. Canada Axial Spondyloarthritis (axSpA) Market Overview

    25.2. Canada Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25.3. Canada Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25.4. Canada Axial Spondyloarthritis (axSpA) Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26. South America Axial Spondyloarthritis (axSpA) Market

    26.1. South America Axial Spondyloarthritis (axSpA) Market Overview

    26.2. South America Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26.3. South America Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26.4. South America Axial Spondyloarthritis (axSpA) Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27. Brazil Axial Spondyloarthritis (axSpA) Market

    27.1. Brazil Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27.2. Brazil Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27.3. Brazil Axial Spondyloarthritis (axSpA) Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28. Middle East Axial Spondyloarthritis (axSpA) Market

    28.1. Middle East Axial Spondyloarthritis (axSpA) Market Overview

    28.2. Middle East Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28.3. Middle East Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28.4. Middle East Axial Spondyloarthritis (axSpA) Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29. Africa Axial Spondyloarthritis (axSpA) Market

    29.1. Africa Axial Spondyloarthritis (axSpA) Market Overview

    29.2. Africa Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29.3. Africa Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29.4. Africa Axial Spondyloarthritis (axSpA) Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    30. Axial Spondyloarthritis (axSpA) Market Competitive Landscape And Company Profiles

    30.1. Axial Spondyloarthritis (axSpA) Market Competitive Landscape

    30.2. Axial Spondyloarthritis (axSpA) Market Company Profiles

    30.2.1. Johnson and Johnson Private Limited

    30.2.1.1. Overview

    30.2.1.2. Products and Services

    30.2.1.3. Strategy

    30.2.1.4. Financial Performance

    30.2.2. Pfizer Inc.

    30.2.2.1. Overview

    30.2.2.2. Products and Services

    30.2.2.3. Strategy

    30.2.2.4. Financial Performance

    30.2.3. F. Hoffmann-La Roche AG

    30.2.3.1. Overview

    30.2.3.2. Products and Services

    30.2.3.3. Strategy

    30.2.3.4. Financial Performance

    30.2.4. Merck and Co. Inc.

    30.2.4.1. Overview

    30.2.4.2. Products and Services

    30.2.4.3. Strategy

    30.2.4.4. Financial Performance

    30.2.5. AbbVie Inc.

    30.2.5.1. Overview

    30.2.5.2. Products and Services

    30.2.5.3. Strategy

    30.2.5.4. Financial Performance

    31. Axial Spondyloarthritis (axSpA) Market Other Major And Innovative Companies

    31.1. Novartis AG

    31.2. Sanofi S.A

    31.3. Bristol-Myers Squibb Company

    31.4. AstraZeneca plc.

    31.5. Abbott Laboratories

    31.6. GSK plc.

    31.7. Eli Lilly and Company

    31.8. Takeda Pharmaceutical Company Limited

    31.9. Gilead Sciences Inc.

    31.10. Teva Pharmaceutical Industries Ltd.

    31.11. Regeneron Pharmaceuticals Inc.

    31.12. Biogen Inc.

    31.13. Vertex Pharmaceuticals Incorporated

    31.14. UCB S.A.

    31.15. Boehringer Ingelheim International GmbH.

    32. Global Axial Spondyloarthritis (axSpA) Market Competitive Benchmarking

    33. Global Axial Spondyloarthritis (axSpA) Market Competitive Dashboard

    34. Key Mergers And Acquisitions In The Axial Spondyloarthritis (axSpA) Market

    35. Axial Spondyloarthritis (axSpA) Market Future Outlook and Potential Analysis

    35.1 Axial Spondyloarthritis (axSpA) Market In 2028 - Countries Offering Most New Opportunities

    35.2 Axial Spondyloarthritis (axSpA) Market In 2028 - Segments Offering Most New Opportunities

    35.3 Axial Spondyloarthritis (axSpA) Market In 2028 - Growth Strategies

    35.3.1 Market Trend Based Strategies

    35.3.2 Competitor Strategies

    36. Appendix

    36.1. Abbreviations

    36.2. Currencies

    36.3. Historic And Forecast Inflation Rates

    36.4. Research Inquiries

    36.5. The Business Research Company

    36.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2018-2023, $ Billion
  • Table 2: Global Forecast Market Growth, 2023-2028F, 2033F, $ Billion
  • Table 3: Global Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 4: Global Axial Spondyloarthritis (axSpA) Market, Segmentation By Commercialized Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 5: Global Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 6: Global Axial Spondyloarthritis (axSpA) Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 7: Global Axial Spondyloarthritis (axSpA) Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 8: Global Axial Spondyloarthritis (axSpA) Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 9: Global Axial Spondyloarthritis (axSpA) Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 10: Asia-Pacific, Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 11: Asia-Pacific, Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 12: Asia-Pacific, Axial Spondyloarthritis (axSpA) Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 13: China, Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 14: China, Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 15: China, Axial Spondyloarthritis (axSpA) Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 16: India, Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 17: India, Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 18: India, Axial Spondyloarthritis (axSpA) Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 19: Japan, Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 20: Japan, Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 21: Japan, Axial Spondyloarthritis (axSpA) Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 22: Australia, Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 23: Australia, Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 24: Australia, Axial Spondyloarthritis (axSpA) Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 25: Indonesia, Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 26: Indonesia, Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 27: Indonesia, Axial Spondyloarthritis (axSpA) Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 28: South Korea, Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 29: South Korea, Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 30: South Korea, Axial Spondyloarthritis (axSpA) Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 31: Western Europe, Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 32: Western Europe, Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 33: Western Europe, Axial Spondyloarthritis (axSpA) Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 34: UK, Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 35: UK, Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 36: UK, Axial Spondyloarthritis (axSpA) Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 37: Germany, Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 38: Germany, Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 39: Germany, Axial Spondyloarthritis (axSpA) Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 40: France, Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 41: France, Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 42: France, Axial Spondyloarthritis (axSpA) Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 43: Italy, Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 44: Italy, Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 45: Italy, Axial Spondyloarthritis (axSpA) Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 46: Spain, Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 47: Spain, Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 48: Spain, Axial Spondyloarthritis (axSpA) Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 49: Eastern Europe, Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 50: Eastern Europe, Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 51: Eastern Europe, Axial Spondyloarthritis (axSpA) Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 52: Russia, Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 53: Russia, Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 54: Russia, Axial Spondyloarthritis (axSpA) Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 55: North America, Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 56: North America, Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 57: North America, Axial Spondyloarthritis (axSpA) Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 58: USA, Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 59: USA, Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 60: USA, Axial Spondyloarthritis (axSpA) Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 61: Canada, Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 62: Canada, Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 63: Canada, Axial Spondyloarthritis (axSpA) Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 64: South America, Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 65: South America, Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 66: South America, Axial Spondyloarthritis (axSpA) Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 67: Brazil, Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 68: Brazil, Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 69: Brazil, Axial Spondyloarthritis (axSpA) Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 70: Middle East, Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 71: Middle East, Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 72: Middle East, Axial Spondyloarthritis (axSpA) Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 73: Africa, Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 74: Africa, Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 75: Africa, Axial Spondyloarthritis (axSpA) Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 76: Johnson and Johnson Private Limited Financial Performance
  • Table 77: Pfizer Inc. Financial Performance
  • Table 78: F. Hoffmann-La Roche AG Financial Performance
  • Table 79: Merck and Co. Inc. Financial Performance
  • Table 80: AbbVie Inc. Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2018-2023, $ Billion
  • Figure 2: Global Forecast Market Growth, 2023-2028F, 2033F, $ Billion
  • Figure 3: Global Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 4: Global Axial Spondyloarthritis (axSpA) Market, Segmentation By Commercialized Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 5: Global Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 6: Global Axial Spondyloarthritis (axSpA) Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 7: Global Axial Spondyloarthritis (axSpA) Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 8: Global Axial Spondyloarthritis (axSpA) Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 9: Global Axial Spondyloarthritis (axSpA) Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 10: Asia-Pacific, Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 11: Asia-Pacific, Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 12: Asia-Pacific, Axial Spondyloarthritis (axSpA) Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 13: China, Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 14: China, Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 15: China, Axial Spondyloarthritis (axSpA) Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 16: India, Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 17: India, Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 18: India, Axial Spondyloarthritis (axSpA) Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 19: Japan, Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 20: Japan, Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 21: Japan, Axial Spondyloarthritis (axSpA) Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 22: Australia, Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 23: Australia, Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 24: Australia, Axial Spondyloarthritis (axSpA) Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 25: Indonesia, Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 26: Indonesia, Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 27: Indonesia, Axial Spondyloarthritis (axSpA) Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 28: South Korea, Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 29: South Korea, Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 30: South Korea, Axial Spondyloarthritis (axSpA) Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 31: Western Europe, Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 32: Western Europe, Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 33: Western Europe, Axial Spondyloarthritis (axSpA) Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 34: UK, Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 35: UK, Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 36: UK, Axial Spondyloarthritis (axSpA) Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 37: Germany, Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 38: Germany, Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 39: Germany, Axial Spondyloarthritis (axSpA) Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 40: France, Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 41: France, Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 42: France, Axial Spondyloarthritis (axSpA) Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 43: Italy, Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 44: Italy, Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 45: Italy, Axial Spondyloarthritis (axSpA) Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 46: Spain, Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 47: Spain, Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 48: Spain, Axial Spondyloarthritis (axSpA) Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 49: Eastern Europe, Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 50: Eastern Europe, Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 51: Eastern Europe, Axial Spondyloarthritis (axSpA) Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 52: Russia, Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 53: Russia, Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 54: Russia, Axial Spondyloarthritis (axSpA) Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 55: North America, Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 56: North America, Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 57: North America, Axial Spondyloarthritis (axSpA) Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 58: USA, Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 59: USA, Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 60: USA, Axial Spondyloarthritis (axSpA) Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 61: Canada, Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 62: Canada, Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 63: Canada, Axial Spondyloarthritis (axSpA) Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 64: South America, Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 65: South America, Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 66: South America, Axial Spondyloarthritis (axSpA) Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 67: Brazil, Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 68: Brazil, Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 69: Brazil, Axial Spondyloarthritis (axSpA) Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 70: Middle East, Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 71: Middle East, Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 72: Middle East, Axial Spondyloarthritis (axSpA) Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 73: Africa, Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 74: Africa, Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 75: Africa, Axial Spondyloarthritis (axSpA) Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 76: Johnson and Johnson Private Limited Financial Performance
  • Figure 77: Pfizer Inc. Financial Performance
  • Figure 78: F. Hoffmann-La Roche AG Financial Performance
  • Figure 79: Merck and Co. Inc. Financial Performance
  • Figure 80: AbbVie Inc. Financial Performance
Forecasting Till 2030: Opportunities And Strategies In The Global Value Based Care Payment Market – Includes Value Based Care Payment Market Analysis
Read More
How Will The Nuclear Medicine Market Grow In 2022?
Read More
What Is The Pediatric Imaging Market Overview In 2022?
Read More
Latest Healthcare Technology Management Market Growth Study 2022-2026 By The Business Research Company
Read More
The Business Research Company offers the hospital acquired infection control market research report 2022 with industry size, share, segments and market growth
Read More
The Business Research Company offers the multiplex assays market research report 2022 with industry size, share, segments and market growth
Read More
The Business Research Company offers the healthcare it consulting market research report 2022 with industry size, share, segments and market growth
Read More
The Business Research Company offers the renal biomarkers market research report 2022 with industry size, share, segments and market growth
Read More
Axial Flow Pump Global Market Report 2024 – By Product Type (Horizontal, Vertical), By Application (Water Treatment, Irrigation, Evaporators, Other Applications), By End-User (Chemical, Municipal, Pulp And Paper, Agriculture, Food And Beverage, Other End-Users) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Satellite Transponders Global Market Report 2024 – By Bandwidth (C Band, Ku Band, Ka Band, K Band), By Service (Leasing, Maintenance & Support), By Application (Commercial Communications, Government Communications, Navigation, Remote Sensing, R&D) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Ankylosing Spondylitis Global Market Report 2024 – By Treatment Type (Painkillers And Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Disease-Modifying Anti-Rheumatic Drugs (DMARDS), Biological Therapies, Steroids, Physical Therapies, Surgery), By Molecule (Biologics, Biosimilar, Small Molecules), By Route of Administration (Parenteral, Oral, Other Routes), By Application (Juveniles, Adults), By End User (Hospitals, Clinics, Research Laboratories, Other End Users) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Cervical Spondylosis Treatment Global Market Report 2024 – By Type of Treatment (Medications, Physical Therapy, Surgery), By Application (Youth, Elderly), By End User (Hospitals, Ambulatory Surgical Centers, Homecare Settings) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Autonomous Military Aircraft Global Market Report 2024 – By Type (Fighter Aircrafts, Bombers, Reconnaissance and Surveillance Aircrafts, Airborne Early Warning Aircrafts, Others), By Component (Flight Management Computers, Air Data Inertial Reference Units, Sensors, Actuation Systems, Software, Intelligent Servos, Cameras, Radars & Transponders, Propulsion Systems), By Technology (Remotely Operated, Semi-Autonomous, Autonomous) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Arthritis Monoclonal Antibodies Global Market Report 2024 – By Drug (Remicade, Humira, Enbrel, Rituxan, Orencia, Actemra, Simponi, Cimzia, Remsima), By Application (Rheumatoid Arthritis, Osteoarthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Fibromyalgia, Other Applications), By End-Use (Hospitals, Research Institutes, Other End-Users) – Market Size, Trends, And Global Forecast 2024-2033
View Report
TNF Alpha Inhibitors Global Market Report 2024 – By Drug (Remicade (Infliximab), Enbrel (Etanercept), Humira (Adalimumab), Cimzia (Certolizumab Pegol), Simponi (Golimumab)), By Route Of Administration (Oral, Subcutaneous, Intravenous, Other Route Of Administration), By Disease Type (Inflammatory Bowel Disease, Psoriatic Arthritis, Ulcerative Colitis (UC), Rheumatoid Arthritis, Ankylosing Spondylitis, Other Disease Types) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Adalimumab, Infliximab and Etanercept Biosimilars Global Market Report 2024 – By Product (Adalimumab Biosimilars, Infliximab Biosimilars, Cipleumab), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Application (Crohn’s Disease, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Ankylosing Spondylitis, Plaque Psoriasis, Other Applications) – Market Size, Trends, And Global Forecast 2024-2033
View Report

Frequently Asked Questions

What is the definition of the axial spondyloarthritis (axSpA) market?

Axial Spondyloarthritis (axSpA) is a chronic inflammatory condition that predominantly impacts the axial skeleton, encompassing the spine and sacroiliac joints. It is characterized by inflammation in the sacroiliac joints, resulting in persistent back pain and stiffness. For further insights on the axial spondyloarthritis (axSpA) market, request a sample here

How will the axial spondyloarthritis (axSpA) market drivers and restraints affect the axial spondyloarthritis (axSpA) market dynamics? What forces will shape the axial spondyloarthritis (axSpA) industry going forward?

The axial spondyloarthritis (axSpA) market major growth driver - Rising Prevalence Of Axial Spondyloarthritis (AXSPA) Is A Catalyst For Market Growth And Advancements In Treatment. For further insights on the axial spondyloarthritis (axSpA) market, request a sample here

What is the forecast market size or the forecast market value of the axial spondyloarthritis (axSpA) market?

The axial spondyloarthritis (axSpA) market size has grown strongly in recent years. It will grow from $5.54 billion in 2023 to $6.04 billion in 2024 at a compound annual growth rate (CAGR) of 9.0%. The growth in the historic period can be attributed to improved diagnostic criteria, biological treatment advancements, rising disease awareness, genetic research advances, clinical trial progress. The axial spondyloarthritis (axSpA) market size is expected to see strong growth in the next few years. It will grow to $8.18 billion in 2028 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period can be attributed to advancements in biomarker identification, tailored therapies, digital health integration, expanded treatment options, healthcare policy support:. Major trends in the forecast period include early intervention strategies, patient-centric care, telemedicine and remote consultations, research on disease mechanisms, shared decision-making. For further insights on the axial spondyloarthritis (axSpA) market, request a sample here

How is the axial spondyloarthritis (axSpA) market segmented?

The axial spondyloarthritis (axSpA) market is segmented
1) By Types: Ankylosing spondylitis (AS), Non-radiographic axial spondyloarthritis (nr-axSpA)
2) By Commercialized Therapies: Anti-tumor Necrosis Factor Therapy (TNF), Anti-Interleukin Therapy (IL), Anti-Janus Kinase Therapy (JAK)
3) By Dosage Form: Tablets, Injections
4) By Treatment: Tumor necrosis factor (TNF) Alpha Inhibitors, Non-steroidal anti-inflammatory drugs (NSAID), Conventional Disease Modifying Anti-Rheumatic Drugs, Glucocorticoids, Interleukin Blockers
5) By End-Use: Hospital Pharmacies, Retailer Pharmacies, Online Pharmacy StoresFor further insights on the axial spondyloarthritis (axSpA) market, request a sample here

Which region has the largest share of the axial spondyloarthritis (axSpA) market? What are the other regions covered in the report?

North America was the largest region in the axial spondyloarthritis(axSpA) market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the axial spondyloarthritis (axSpA) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa For further insights on the axial spondyloarthritis (axSpA) market, request a sample here.

Who are the major players in the axial spondyloarthritis (axSpA) market?

Major companies operating in the axial spondyloarthritis (axSpA) market report are Johnson and Johnson Private Limited, Pfizer Inc., F. Hoffmann-La Roche AG, Merck and Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A, Bristol-Myers Squibb Company, AstraZeneca plc., Abbott Laboratories, GSK plc., Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Biogen Inc., Vertex Pharmaceuticals Incorporated, UCB S.A., Boehringer Ingelheim International GmbH., Horizon Therapeutics Public Ltd Co, Mitsubishi Tanabe Pharma Corporation, Ipsen Technologies Pvt Ltd., Kyowa Kirin Co. Ltd., Sun Pharmaceutical Industries Ltd., Acelyrin Inc., Nordic Bioscience A/S, Iroko Pharmaceuticals LLC, Celgene Corporation, Pozen Inc. For further insights on the axial spondyloarthritis (axSpA) market, request a sample here.

What are the key trends in the axial spondyloarthritis (axSpA) market?

Major trend in the axial spondyloarthritis (axSpA) market - UCB Sa Secures Eu Approval For Bimzelx In Treating Axial Spondyloarthritis (AXSPA). For further insights on the axial spondyloarthritis (axSpA) market, request a sample here.

What are the major opportunities in the axial spondyloarthritis (axSpA) market? What are the strategies for the axial spondyloarthritis (axSpA) market?

For detailed insights on the major opportunities and strategies in the axial spondyloarthritis (axSpA) market, request a sample here.

How does the axial spondyloarthritis (axSpA) market relate to the overall economy and other similar markets?

For detailed insights on axial spondyloarthritis (axSpA) market's relation to the overall economy and other similar markets, request a sample here.

What are the latest mergers and acquisitions in the axial spondyloarthritis (axSpA) industry?

For detailed insights on the mergers and acquisitions in the axial spondyloarthritis (axSpA) industry, request a sample here.

What are the key dynamics influencing the axial spondyloarthritis (axSpA) market growth? SWOT analysis of the axial spondyloarthritis (axSpA) market.

For detailed insights on the key dynamics influencing the axial spondyloarthritis (axSpA) market growth and SWOT analysis of the axial spondyloarthritis (axSpA) industry, request a sample here.